AVITA Medical (RCEL) Panoramica del titolo
AVITA Medical, Inc. insieme alle sue consociate, opera come società di cura delle ferite acute negli Stati Uniti, in Giappone, nell'Unione Europea, in Australia e nel Regno Unito. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 0/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
RCEL Community Fair Values
Create NarrativeSee what 42 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di AVITA Medical, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$8.20 |
| Massimo di 52 settimane | US$8.35 |
| Minimo di 52 settimane | US$3.22 |
| Beta | 1.85 |
| Variazione di 1 mese | 101.97% |
| Variazione a 3 mesi | 92.49% |
| Variazione di 1 anno | 48.55% |
| Variazione a 3 anni | -53.46% |
| Variazione a 5 anni | -51.74% |
| Variazione dall'IPO | -67.20% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Aug 10
RCEL: Rich Multiple Will Face Pressure If Utilization Momentum Fades
Analysts have lifted their consolidated price target for AVITA Medical stock from $5.49 to $7.04, citing recent Q2 results that were described as a significant beat with improved guidance, broader RECELL utilization, and stabilizing reimbursement trends. Analyst Commentary Recent Street research on AVITA Medical points to a more constructive tone following the latest Q2 update.
Aggiornamento narrativa • Jul 27
RCEL: Execution And Cash Strength Will Support Recovery And Multiple Expansion
Analysts have lifted their price targets on AVITA Medical stock from about $6 to $12. They point to continued uptake of RECELL, expectations for steady organic revenue growth with solid margins, and sufficient support for the company’s working capital needs as key factors behind the shift.Recent updates
Aggiornamento narrativa • Aug 10
RCEL: Rich Multiple Will Face Pressure If Utilization Momentum Fades
Analysts have lifted their consolidated price target for AVITA Medical stock from $5.49 to $7.04, citing recent Q2 results that were described as a significant beat with improved guidance, broader RECELL utilization, and stabilizing reimbursement trends. Analyst Commentary Recent Street research on AVITA Medical points to a more constructive tone following the latest Q2 update.Aggiornamento narrativa • Jul 27
RCEL: Execution And Cash Strength Will Support Recovery And Multiple Expansion
Analysts have lifted their price targets on AVITA Medical stock from about $6 to $12. They point to continued uptake of RECELL, expectations for steady organic revenue growth with solid margins, and sufficient support for the company’s working capital needs as key factors behind the shift.
Aggiornamento narrativa • Jul 13
RCEL: Renewed Adoption Confidence Will Support Future Bullish Repricing
Analysts have raised their consolidated price target for AVITA Medical from $5.50 to $12, pointing to renewed confidence in RECELL adoption, expectations for organic revenue momentum, and views that the company has sufficient flexibility to support working capital needs. Analyst Commentary Recent research on AVITA Medical highlights a cluster of upbeat views around RECELL adoption, revenue momentum, and balance sheet flexibility, but also leaves room for questions about how consistently the company can execute against expectations.Aggiornamento narrativa • Jun 29
RCEL: Execution And Cash Strength Will Drive Recovery And Multiple Expansion
Analysts have raised their price target on AVITA Medical to $6.00 from $3.50. They point to recent quarterly revenue performance, expectations for execution in line with or better than guidance, and an improved cash position as key reasons for a higher fair value estimate and a lower future P/E assumption in updated models.Aggiornamento narrativa • Jun 14
RCEL: Execution And Cash Strength Are Expected To Drive Future Upside
Narrative update The analyst price target for AVITA Medical has risen by $2.50 to $6.00, with analysts highlighting the recent stock pullback, the latest Q1 revenue level, and expectations for execution and cash position as key supports for this revision. Analyst Commentary Bullish analysts are pointing to the recent price target reset and rating change as a sign of renewed confidence in AVITA Medical after the latest quarterly update.Aggiornamento narrativa • May 31
RCEL: Market Recovery And Cash Progress Are Expected To Drive Upside
Analysts have slightly adjusted the AVITA Medical price target to reflect updated assumptions for growth, margins and future P/E. They continue to reference Street research that highlights improving execution, Lake Street’s higher $6 target, and Northland's $10 target supported by expectations for revenue recovery, cash progress and a large addressable market.Aggiornamento narrativa • May 10
RCEL: Low Market Penetration And FY27 Cash Breakeven Will Drive Repricing
Analysts have trimmed their price target for AVITA Medical to $5.49 from $5.52, reflecting updated assumptions on discount rate, revenue growth, profit margin, and future P/E after recent research highlighted low current market penetration, a roughly $1.3b total addressable market, reimbursement stabilization, and an outlook for potential cash breakeven during FY27. Analyst Commentary Recent research points to a mixed backdrop for AVITA Medical, with analysts updating their models around a roughly $1.3b total addressable market, low current market penetration of about 5%, and expectations tied to reimbursement trends and the path toward a potential cash breakeven during FY27.Aggiornamento narrativa • Apr 25
RCEL: Market Penetration And Burn Preparedness Agreement Will Support Constructive Upside
Narrative Update on AVITA Medical The Analyst Price Target for AVITA Medical has been adjusted from $10.02 to about $10.16. Analysts point to updated views on revenue growth and profit margins, as well as recent Northland research highlighting market penetration, product differentiation, reimbursement trends and the path toward cash breakeven as key supports for this change.Aggiornamento narrativa • Apr 11
RCEL: Reimbursement Stability And FY27 Cash Breakeven Frame Balanced Risk Reward Outlook
The analyst price target for AVITA Medical has been revised slightly higher to reflect an updated fair value of about $5.52, up from roughly $5.33. Analysts point to expectations for revenue growth, stable profit margins, and recent research citing product differentiation, reimbursement stabilization, and progress toward cash breakeven as key drivers of their refreshed view.Aggiornamento narrativa • Mar 28
RCEL: Reimbursement Stability And FY27 Cash Breakeven Drive Bullish Rerating Potential
Analysts have trimmed their blended valuation for AVITA Medical, with the updated fair value estimate easing from about $5.44 to $5.33 per share. This reflects revised assumptions on revenue growth, profit margins, and a lower future P/E multiple informed by recent research that highlights both the pullback in the stock and expectations for double digit top line expansion over time.Aggiornamento narrativa • Mar 13
RCEL: Reimbursement Stability And Cash Breakeven Path Will Underpin Renewed Market Confidence
Analysts have lifted their AVITA Medical price target to $10, supported by expectations for renewed double digit revenue growth from a roughly $1.3b addressable market, reimbursement stabilization, and a path to potential cash breakeven around FY27. Analyst Commentary Recent coverage has highlighted a mixed but generally constructive view on AVITA Medical, with the latest initiation pointing to a $10 price target.Aggiornamento narrativa • Feb 27
RCEL: Refined Earnings Assumptions And Burn Data Will Support Constructive Upside
Analysts have nudged their average price target on AVITA Medical up by $0.50 per share, citing updated assumptions around revenue growth, profit margins and P/E multiples that modestly refine their valuation models. Analyst Commentary Recent bullish analysts have framed the $0.50 uplift in the average price target as a refinement rather than a wholesale reset.Aggiornamento narrativa • Feb 13
RCEL: Ongoing Burn And Wound Data Will Support Constructive Long-Term Upside
Analysts have adjusted their price target on AVITA Medical to $10.07 from $14.10, reflecting updated views on fair value, discount rate, revenue growth and profit margin assumptions that are broadly consistent with recent Street research, including the modest target raise cited by Lake Street. Analyst Commentary Recent price target work on AVITA Medical points to a more constructive tone among bullish analysts, even if some models still embed conservative assumptions on execution and profitability.Aggiornamento narrativa • Jan 30
RCEL: Elevated Expectations For 2026 Guidance Will Expose Fragile Market Confidence
Narrative Update: AVITA Medical Analysts have raised their price target on AVITA Medical to about US$3.61 from roughly US$3.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E as key factors behind the revised assessment. Analyst Commentary Even with a higher price target around US$3.61, bearish analysts remain cautious and describe the move as a fine tuning of assumptions rather than a strong endorsement of upside potential.Articolo di analisi • Jan 24
There's No Escaping AVITA Medical, Inc.'s (NASDAQ:RCEL) Muted Revenues Despite A 26% Share Price Rise
AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders would be excited to see that the share price has had a great month...Aggiornamento narrativa • Jan 16
RCEL: Two Year Revenue Guidance Reset Will Support Bullish Repricing
Analysts have adjusted their price target for AVITA Medical, reflecting a lower implied fair value of $6.98, down from $7.32. They cite updated assumptions around revenue growth, profit margins, and a reduced future P/E multiple.Articolo di analisi • Nov 09
AVITA Medical, Inc. (NASDAQ:RCEL) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
AVITA Medical, Inc. ( NASDAQ:RCEL ) missed earnings with its latest quarterly results, disappointing overly-optimistic...Aggiornamento narrativa • Nov 08
RCEL: Leadership Transition And Guidance Reset Will Drive Second Half Recovery
Analysts have lowered their price target for AVITA Medical from $8.00 to $4.00. They cite weaker-than-expected Q3 revenue, leadership changes, and the need to amend debt agreements as key factors in their revised outlook.Articolo di analisi • Oct 03
AVITA Medical, Inc. (NASDAQ:RCEL) Surges 28% Yet Its Low P/S Is No Reason For Excitement
AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders would be excited to see that the share price has had a great month...Aggiornamento narrativa • Sep 17
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
Analysts have markedly reduced AVITA Medical’s price target from $9.60 to $8.26 amid lowered guidance, recurring earnings misses, and ongoing reimbursement headwinds that are pressuring demand and raising solvency concerns despite management’s optimism for a second-half recovery. Analyst Commentary Materially lowered guidance has prompted a significant reset of expectations, but management maintains confidence in a second half recovery.Aggiornamento narrativa • Aug 15
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
AVITA Medical’s consensus price target remains unchanged as analysts respond to materially reduced guidance and persistent reimbursement issues—with bulls viewing the lowered expectations as prudent and bears citing execution risks and near-term revenue headwinds—leaving the fair value steady at $9.60. Analyst Commentary Materially reduced guidance led to significant downward revisions in price targets.Articolo di analisi • Aug 10
AVITA Medical, Inc. (NASDAQ:RCEL) Not Doing Enough For Some Investors As Its Shares Slump 25%
Unfortunately for some shareholders, the AVITA Medical, Inc. ( NASDAQ:RCEL ) share price has dived 25% in the last...Articolo di analisi • May 29
Shareholders Will Probably Not Have Any Issues With AVITA Medical, Inc.'s (NASDAQ:RCEL) CEO Compensation
Key Insights AVITA Medical will host its Annual General Meeting on 4th of June CEO Jim Corbett's total compensation...
Nuova narrativa • Apr 24
PermeaDerm And Cohealyx Will Open International Markets
Launching new products and expanding internationally are expected to drive significant revenue growth and market penetration.Articolo di analisi • Mar 06
Investors Don't See Light At End Of AVITA Medical, Inc.'s (NASDAQ:RCEL) Tunnel
AVITA Medical, Inc.'s ( NASDAQ:RCEL ) price-to-sales (or "P/S") ratio of 3.5x might make it look like a strong buy...Rendimenti per gli azionisti
| RCEL | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | 77.1% | 4.9% | 0.09% |
| 1Y | 48.6% | 41.3% | 19.0% |
Ritorno vs Industria: RCEL ha superato il US Biotechs che ha restituito 41.3 % nell'ultimo anno.
Rendimento vs Mercato: RCEL ha superato il mercato US che ha restituito 19 % nell'ultimo anno.
Volatilità dei prezzi
| RCEL volatility | |
|---|---|
| RCEL Average Weekly Movement | 20.6% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di RCEL è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di RCEL è aumentata da 15% a 21% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| n/a | 226 | Cary Vance | avitamedical.com |
AVITA Medical, Inc. opera, insieme alle sue consociate, come società di cura delle ferite acute negli Stati Uniti, in Giappone, nell'Unione Europea, in Australia e nel Regno Unito. Il prodotto di punta dell'azienda è il sistema RECELL, un dispositivo per la raccolta di cellule utilizzato per il trattamento delle ferite da ustione termica e dei difetti cutanei a tutto spessore, nonché per la ripigmentazione delle lesioni depigmentate stabili della vitiligine. Fornisce inoltre il dispositivo per il prelievo di cellule autologhe RECALL, che può trattare aree fino a 1.920 cm2; il dispositivo per il prelievo di cellule autologhe RECELL con facilità d'uso, un dispositivo potenziato di facile utilizzo che può trattare aree fino a 1.920 cm²; e RECELL GO mini dispositivo di raccolta di cellule autologhe, un'estensione del sistema RECELL GO per il trattamento di ferite più piccole fino a 480 cm2, nonché RECELL GO dispositivo di raccolta di cellule autologhe composto dal dispositivo di lavorazione RECELL GO, che controlla e gestisce la pressione applicata per disaggregare le cellule cutanee del donatore e controlla il tempo di incubazione dell'enzima RECELL per ottimizzare la resa delle cellule e promuoverne la vitalità, e dal kit di preparazione RECELL GO, che può trattare aree fino a 1.920 cm2.
AVITA Medical, Inc. Riepilogo dei fondamenti
| RCEL statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$235.04m |
| Utili (TTM) | -US$43.08m |
| Ricavi(TTM) | US$75.63m |
3.4x
Rapporto P/S-5.9x
Rapporto P/ERCEL è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| RCEL Conto economico (TTM) | |
|---|---|
| Ricavi | US$75.63m |
| Costo del fatturato | US$13.95m |
| Profitto lordo | US$61.68m |
| Altre spese | US$104.76m |
| Utili | -US$43.08m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -1.39 |
| Margine lordo | 81.56% |
| Margine di profitto netto | -56.96% |
| Rapporto debito/patrimonio netto | -167.6% |
Come si è comportato RCEL nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/11 04:36 |
| Prezzo dell'azione a fine giornata | 2026/08/11 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
AVITA Medical, Inc. è coperta da 15 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| John Hester | Bell Potter |
| Brenton Anderson | Bell Potter |
| Lyanne Harrison | BofA Global Research |